The treatment for glioblastoma multiforme (GBM) has not changed for more than 20 years while the prognosis for the patients is still poor and most of them survive less than 1 year after diagnosis. The standard of care for GBM is comprised of surgical resection followed by radiotherapy and oral chemotherapy with temozolomide. The placement of carmustine wafers in the brain after tumour removal is added in cases of recurrent glioma. Significant research is underway to improve the GBM therapy outcome and patient quality of life. Biomaterials are in the front line of the research focus for new treatment options. Specially, biocompatible polymers have been proposed in hydrogel-based formulations aiming at injectable and localized therapies. These formulations can comprise many different pharmacological agents such as chemotherapeutic drugs, nanoparticles, cells, nucleic acids, and diagnostic agents. In this manuscript, we review the most recent formulations developed and tested both in vitro and in vivo using different types of hydrogels. Firstly, we describe three common types of thermo-responsive polymers addressing the advantages and drawbacks of their formulations. Then, we focus on formulations specifically developed for GBM treatment.

多形性胶质母细胞瘤（GBM）的治疗方法没有改变超过20年，而患者的预后仍然很差，并且大多数患者在诊断后不到一年即可生存。GBM的标准护理包括外科切除，放疗和替莫唑胺口服化疗。在复发性神经胶质瘤的情况下，增加了去除肿瘤后脑中卡莫司汀片的位置。正在进行大量研究以改善GBM治疗结果和患者生活质量。生物材料是新治疗方案的研究重点。特别地，已经针对基于水凝胶的制剂提出了生物相容性聚合物，旨在用于注射和局部疗法。这些制剂可以包含许多不同的药物，例如化疗药物，纳米粒子，细胞，核酸和诊断剂。在本手稿中，我们回顾了开发和测试的最新配方在体外和体内使用不同类型的水凝胶。首先，我们描述三种常见类型的热敏性聚合物，以解决其配方的优缺点。然后，我们专注于专门为GBM治疗而开发的配方。